2022 World Conference on Lung Cancer (ePosters)-EP08.02-061. Treatment Sequences in ALK-rearranged Non-small Cell Lung Cancer; What Happens in the Real World?

EP08.02-061. Treatment Sequences in ALK-rearranged Non-small Cell Lung Cancer; What Happens in the Real World?

Pdf Summary

This study examines the treatment patterns, prognostic factors, and survival outcomes of patients with ALK-rearranged advanced non-small cell lung cancer (aNSCLC) in a real-world cohort. The authors note that ALK-rearrangements can be found in 3-5% of patients with aNSCLC, and there are multiple agents available to manage these patients, including tyrosine kinase inhibitors, chemotherapy, and immunotherapy.<br /><br />The authors analyzed data from the Flatiron Health electronic health record database, which included de-identified patient data from approximately 280 US cancer clinics. The study included patients diagnosed with aNSCLC between 2011-2020 who had a positive ALK test and at least 90 days of follow-up.<br /><br />The results showed that 38% of patients received at least three lines of treatment. The most common treatment sequence among those who had three lines of treatment was chemotherapy followed by crizotinib followed by a second-generation ALK inhibitor. The use of lorlatinib was limited, likely due to the timing of FDA approval.<br /><br />The median overall survival for the real-world cohort was 38 months, which appeared to increase over time from 2013/2014-2017/2018. However, the overall survival in this cohort was still lower than that reported in clinical trials and academic center registries.<br /><br />The authors conclude that real-world survival data and consensus on the best treatment sequence for ALK-rearranged aNSCLC are lacking. They suggest that analyzing the impact of treatment sequence on survival in this cohort may help guide clinical practice. Overall, this study provides insights into the treatment patterns and survival outcomes of patients with ALK-rearranged aNSCLC in a real-world setting.

Asset Subtitle

Grace Chazan

Meta Tag

Speaker Grace Chazan

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

ALK-rearranged

advanced non-small cell lung cancer

treatment patterns

prognostic factors

survival outcomes

real-world cohort

tyrosine kinase inhibitors

chemotherapy

immunotherapy

overall survival